Pharma Mar

1H 2022 Results Presentation

Madrid, July 28th 2022

Disclaimer

This presentation might include forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity, results of operation, clinical program, plans and objectives of Pharma Mar, S.A. ("PharmaMar" or the "Company"). These forward-looking statements can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “endeavor,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. These forward-looking statements are based on the expectations of management under current assumptions at the time of this presentation, are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to materially differ from those contained in the forward-looking statements. All forward-looking statements in this presentation apply only as of the date made. Except as required by law, the Company is not obligated to, and does not intend to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To the extent that this presentation contains market data, industry statistics and other data that have been obtained from, or compiled from, information made available by third parties, the Company has not independently verified their data.

AGENDA

1. FINANCIAL HIGHLIGHTS
2. OPERATIONAL UPDATE
3. US UPDATE
4. Q&A & CLOSING REMARKS

José Luis Moreno
Director Capital Markets
and Investor Relations

The plan for growth

On track to deliver value to shareholders

FURTHER DEVELOPMENT WITH LURBINECTEDIN

- Phase 3 trial with lurbinectedin in SCLC for EU approval and US confirmatory
- Phase 3 trial with lurbinectedin in other indications
- Potential lurbinectedin approvals in other countries

OTHER DRUGS DEVELOPMENT

- 2 Phase 2 trials for PM14 planned to start in 2021 and 2022
- 2 new compounds to enter Phase 1

CORPORATE DEVELOPMENT

- Looking for in-licensing products to market in EU
- Profitable with robust cash position

AGENDA

1. FINANCIAL HIGHLIGHTS
2. OPERATIONAL UPDATE
3. US UPDATE
4. Q&A & CLOSING REMARKS

Mª Luisa de Francia
Chief Financial Officer

Main financial figures

Revenues Evolution *(€mn)*

Total Revenues



Recurring revenues breakdown





Oncology sales breakdown (€mn)



Main financial figures

Increasing R+D Investment 39% compared to June'21 *(€mn)*

R&D Expenses



Other operating expenses



Cash position

Solid net cash position *(€mn)*



Net cash position **has increased c26%** from December 2021 to June 2022.

This increase **allows the Company** to continue with its Corporate business plan.

AGENDA

1. FINANCIAL HIGHLIGHTS
2. OPERATIONAL UPDATE
3. US UPDATE
4. Q&A & CLOSING REMARKS

Luis Mora
Managing Director

Pipeline
Oncology



(1) Approved in Australia
(2) Investigator Sponsored Trial

Oncology: Lurbinectedin

Regulatory update:

Filings and reimbursement	Countries	Estim. date
Dossiers filed for approval (SCLC)	UK, Switzerland, Brazil, Mexico, Argentina, Colombia	Dic'22-1Q'23
Negotiating reimbursements	Canada, Singapore, UAE, Australia, Qatar	NA

	Countries
Early access program	France, China, others

Clinical update:

Trials	Status	End Date
LAGOON Trial (SLCL) 2L	Recruiting	2025
IMforte Trial (SCLC) 1L Maintenance	Recruiting	2025
Mesothelioma (Lurbi+IO) 2L	To start 2022	

Pipeline
RNAi and Virology

sylentis : RNAi



Virology

New trial planned: to start a phase II trial in immunosuppressed patients

AGENDA

1. FINANCIAL HIGHLIGHTS
2. OPERATIONAL UPDATE
3. US UPDATE
4. Q&A & CLOSING REMARKS

Pascal Besman
Chief Operating Officer of Pharmamar US

Lurbinectedin
Recent studies



ELSEVIER

European Journal of Cancer
Volume 172, September 2022, Pages 357-366

Original Research

Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma ☆

Daphne W. Dumoulin [a, 1], Luca Cantini [a, b, 1], Robin Cornelissen [a], Madelief Vink [a], Larissa Klaase [a], Kick Sloof [a], Nura Tebayna [a], Joanne M. Mankor [a], Sara J. Baart [a, c], Rudi Hendriks [a], Anne-Marie C. Dingemans [a], Marcella Willemsen [a, 2], Joachim G.J.V. Aerts [a] ✉

First Prospective **Real World** data, coming from Named Patient Program

- Heavily pre-treated SCLC (n=43) and MPM (n=52)
- Mostly ≥3rd line
- SCLC 72% Resistant/Refractory
- Cross trial comparison of SCLC sees lurbinectedin ORR 16% vs. Topotecan ORR 5% refractory, 17% sensitive
- Study demonstrates that lurbinectedin induces a relative reduction of circulating classical monocytes, which “suggests that the combination of lurbinectedin with immunotherapy might be efficacious.”

IASLC 2022 World Conference on Lung Cancer
AUGUST 6-9, 2022 | VIENNA, AUSTRIA

Characterization of **Real-World Use** of Lurbinectedin in **Adult Small Cell Lung Cancer Patients in the United States**, B Rengarajan et al
Data (using Flatiron HER database)

- Pts treated with lurbinectedin between June 2020 (FDA Approval) and October 2021. However, presentation will be data up to April 2022
- Comparing abstract to final presentation, can see that as data has matured, fewer 3-4L pts now and more 2L
- Should expect to see an increase in average cycles as more 2L patients
- Reflects that physicians are comfortable using lurbinectedin in any patient, and broadly in 2nd line.

Pharma Mar

Lurbinectedin

Emerging lurbinectedin ISTs; Broadening reach in SCLC, and beyond SCLC

- Combo **radiation** in SCLC, Emory (TiP poster at IASLC)
- PHARMACLIN, **Real World** data from ATU in France
- **Durvalumab** + (Lurbinectedin or Topotecan) in rSCLC; Mayo/NCI

AGENDA

1. FINANCIAL HIGHLIGHTS
2. OPERATIONAL UPDATE
3. US UPDATE
4. Q&A & CLOSING REMARKS

José Luis Moreno
Director Capital Markets and Investor Relations


Pharma
Mar